J&J Could Score Priority Review Voucher with Bedaquiline NDA

Janssen Research and Development, part of J&J, has asked the FDA to approve bedaquiline, a diarylquinoline to treat multi-drug resistant tuberculosis. If given the green light, bedaquiline would be the first drug with a new mechanism of action to be approved for tuberculosis in over four decades. Janssen points out that the pill would also be the first drug approved for multi-drug resistant TB. If approved, Johnson & Johnson...

Read More
Francis Collins At TEDMED – Repurposing Drugs, Replacing Animal Models, Rocking Out
Apr11

Francis Collins At TEDMED – Repurposing Drugs, Replacing Animal Models, Rocking Out

You know you’re at an interesting conference when the director of the NIH starts off his presentation with a guitar duet, and shares a session with Cookie Monster. But the organizers of TEDMED made a very deliberate decision in opening this year’s conference with Francis Collins. This is the first year that the gathering of medical luminaries, artists, and design gurus (TED stands for Technology, Entertainment, Design) is...

Read More
Using Gene Expression Patterns to Repurpose Drugs
Nov14

Using Gene Expression Patterns to Repurpose Drugs

Late last month, researchers from many different fields gathered at the Computer History Museum in Mountain View, California, to discuss the benefits of open science and data sharing. One of the best talks from that event, the Open Science Summit, was delivered by Joel Dudley, the co-founder of NuMedii, a firm that aims to find new indications for medications. Dudley has repeatedly found new uses for old drugs by picking through...

Read More
Drugs to Stop the “Brain-Eating Amoeba” N. fowleri
Aug25

Drugs to Stop the “Brain-Eating Amoeba” N. fowleri

Summer can be hot, and many people cool down by jumping in nearby lakes and rivers. However, that’s also where millions of microbes like to play: as reported by multiple news outlets, the third 2011 US death has now been attributed to what the popular press has dubbed “the brain-eating amoeba.” This “amoeba,” actually a protist called Naegleria fowleri, has been known to medicine since 1965. It belongs to a completely different...

Read More

AstraZeneca, MMV in Malaria Research Pact

Yet another company is opening up its molecular vault to help speed the development of drugs for neglected diseases. AstraZeneca will allow the non-profit Medicines to sift through the 500,000 compounds in its library to test for activity against P. falciparum, the worst of the malaria parasites. MMV has enlisted Vicky Avery, professor at the Eskitis Institute for Cell and Molecular Therapies at Griffith University in Brisbane,...

Read More

More On Malaria Open Innovation Announcement

A slew of molecules that might lead to the next antimalarial drug are up for grabs, now that GlaxoSmithKline, the Genomics Institute of the Novartis Research Foundation, and a consortium led by a St. Jude Children’s Research Hospital team have released their data into the public domain. As I wrote today, this is great news for the malaria community, which has to do drug discovery on a shoestring compared to, say, the oncology...

Read More